Physician profile
Richard Brooks
NPI 1053360487
$1,977.14
in general payments reported to CMS, 2019-2025
33 companies · $18.02 in 2025
The $18.02 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.84 · 2020: $141 · 2021: $178 · 2022: $456 · 2023: $820 · 2024: $309 · 2025: $18.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,147.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $341.28 | 2022-2024 | Qulipta, Ubrelvy |
| Biogen, INC. | $221.52 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $131.13 | 2019-2024 | Austedo Xr, Austedo |
| Lilly USA, LLC | $130.09 | 2019-2024 | Amyvid |
| Neurelis, INC. | $111.27 | 2022-2024 | Valtoco |
| Lundbeck LLC | $109.03 | 2023-2024 | Vyepti |
| Neurocrine Biosciences, INC. | $102.61 | 2022-2024 | Ingrezza, Ongentys |
| Harmony Biosciences LLC | $73.18 | 2022-2023 | Wakix |
| Biohaven Pharmaceutical Holding Company LTD. | $53.70 | 2022 | |
| Alexion Pharmaceuticals, INC. | $53.25 | 2023 | Ultomiris, Soliris |
| Kyowa Kirin, INC. | $53.06 | 2021-2023 | Nourianz |
| Tanabe Pharma America, INC. | $51.12 | 2023 | |
| Sk Life Science, INC. | $48.88 | 2023-2024 | |
| Amneal Pharmaceuticals LLC | $39.28 | 2023-2024 | Rytary |
| E.R. Squibb & Sons, L.L.C. | $37.62 | 2023 | Zeposia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $37.14 | 2020 | |
| Upsher-Smith Laboratories LLC | $36.81 | 2022-2023 | |
| Boston Scientific Corporation | $35.03 | 2024-2025 | Autotome Rx 49, Resolution 360 Clip |
| Cala Health, INC. | $33.56 | 2024 | Cala Trio, Cala Kiq |
| Catalyst Pharmaceuticals, INC. | $28.73 | 2023 | Firdapse |
| Azurity Pharmaceuticals, INC. | $27.35 | 2023 | Horizant |
| Argenx US, INC. | $27.03 | 2022 | |
| Merz Pharmaceuticals, LLC | $23.24 | 2023 | Xeomin |
| Idorsia Pharmaceuticals US INC | $23.06 | 2024 | Quviviq |
| Acorda Therapeutics, INC | $21.30 | 2024 | Inbrija |
| Amgen INC. | $20.89 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $18.36 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18.25 | 2021 | |
| Jazz Pharmaceuticals INC. | $15.55 | 2021 | |
| Genzyme Corporation | $15.31 | 2020 | |
| Genentech USA, INC. | $13.87 | 2020 | |
| Emd Serono, INC. | $13.35 | 2019 | |
| Pfizer INC. | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.